G6PC2 抗体 (AA 31-130)
Quick Overview for G6PC2 抗体 (AA 31-130) (ABIN1714378)
抗原
适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 31-130
-
交叉反应
- 人
-
预测反应
- Mouse,Rat,Cow,Sheep,Horse,Rabbit
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human Glucose 6 phosphatase 2/IGRP
-
亚型
- IgG
-
-
anti-Glucose-6-Phosphatase, Catalytic, 2 (G6PC2) (AA 78-115) antibody
G6PC2 适用: 人 ELISA, IHC, IF 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
-
WB 1:300-5000
ELISA 1:500-1000 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
有效期
- 12 months
-
-
- G6PC2 (Glucose-6-Phosphatase, Catalytic, 2 (G6PC2))
-
别名
- Glucose 6 phosphatase 2/IGRP
-
背景
-
Synonyms: G 6 Pase 2, G 6 Pase2, G6Pase 2, G6Pase2, G6PC 2, G6pc rs, G6pcrs, Glucose 6 phosphatase 2, Glucose 6 phosphatase, catalytic, 2, Glucose 6 phosphatase, catalytic, related, Glucose 6 phosphate catalytic 2, Islet specic G6CP related protein, Islet specic glucose 6 phosphatase, Islet specic glucose 6 phosphatase catalytic subunit related protein, G6PC2_HUMAN.
Background: Glucose-6-phosphatase (G6Pase), is a multicomponent enzyme system that hydrolyzes glucose-6-phosphate in the final step of gluconeogenesis and gluconeolysis. G6Pase localizes to the endoplasmic reticulum, and while liver, kidney, and intestine are the only tissues that express the first identified isoform, G6Pase-alpha, a second form, designated G6Pase-, contributes to blood glucose homeostasis in a wider range of tissues. Islet-specific G-6-Pase catalytic subunit-related protein (IGRP), a homolog of the catalytic subunit of G6Pase, may play a role in the regulation of islet metabolism and in insulin secretion induced by metabolites. The exact catalytic acivity of IGRP is not defined. Identification of inhibitors of IGRP have potential therapeutic benefits for treatment of type 2 diabetes resulting from insulin secretion defects. Structurally, IGRP has been shown to be a glycoprotein held in the endoplasmic reticulum by nine transmembrane domains, which are then degraded in cells through the proteasome pathway generating MHC class I presented peptides.
-
基因ID
- 57818
抗原
-
